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Background: Preoperative anemia is a common and potentially serious hematological problem in elective surgery
and increases the risk for perioperative red blood cell (RBC) transfusion. Transfusion is associated with postoperative
morbidity and mortality. Preoperative intravenous (IV) iron therapy has been proposed as an intervention to reduce
perioperative transfusion; however, studies are generally small, limited, and inconclusive.
Methods/Design: We propose performing a systematic review and meta-analysis. We will search MEDLINE, EMBASE,
EBM Reviews, Cochrane-controlled trial registry, Scopus, registries of health technology assessment and clinical trials,
Web of Science, ProQuest Dissertations and Theses, and conference proceedings in transfusion, hematology, and
surgery. We will contact our study drug manufacturer for unpublished trials. Titles and abstracts will be identified
and assessed by two reviewers for potential relevance. Eligible studies are: randomized or quasi-randomized clinical
trials comparing preoperative administration of IV iron with placebo or standard of care to reduce perioperative
blood transfusion in anemic patients undergoing major surgery. Screening, data extraction, and quality appraisal
will be conducted independently by two authors. Data will be presented in evidence tables and in meta-analytic
forest plots.
Primary efficacy outcomes are change in hemoglobin concentration and proportion of patients requiring RBC
transfusion. Secondary outcomes include number of units of blood or blood products transfused perioperatively,
transfusion-related acute lung injury, neurologic complications, adverse events, postoperative infections, cardiopulmonary
complications, intensive care unit (ICU) admission/readmission, length of hospital stay, acute kidney injury, and mortality.
Dichotomous outcomes will be reported as pooled relative risks and 95% confidence intervals. Continuous
outcomes will be reported using calculated weighted mean differences. Meta-regression will be performed to
evaluate the impact of potential confounding variables on study effect estimates.
Discussion: Reducing unnecessary RBC transfusions in perioperative medicine is a clinical priority. This involves
the identification of patients at risk of receiving transfusions along with blood conservation strategies. Of potential
pharmacological blood conservation strategies, IV iron is a compelling intervention to treat preoperative anemia;
however, existing data are uncertain. We propose performing a systematic review and meta-analysis evaluating the
efficacy and safety of IV iron administration to anemic patients undergoing major surgery to reduce transfusion
and perioperative morbidity and mortality.
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Table 1 Current strategies for perioperative blood
conservation
Conservation strategy Examples




c. Recombinant factor VIIa (rFVIIa)
d. Erythropoietin (EPO)
e. Topical haemostatic agents
2. Autologous blood
transfusion
a. Preoperative autologous blood
donation
b. Acute normovolemic hemodilution
c. Red cell salvage (intraoperative and
postoperative)
3. Anesthetic techniques a. Controlled hypotension
b. Spinal or epidural anesthesia
c. Central venous pressure (CVP)
manipulation
4. Surgical techniques a. Coagulation diathermy devices, lasers,
and ultrasonic scalpels
b. Minimally invasive surgery
c. Endoscopic and laparoscopic surgery
5. Blood substitutes a. Solutions of modified hemoglobin
b. Perfluorocarbon emulsions
6. Transfusion protocols,
guidelines, and clinical audit
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Epidemiology of preoperative anemia
Anemia is defined by the World Health Organization
(WHO) as a hemoglobin concentration less than 13 g/dL
in men and 12 g/dL in women [1]. Preoperative anemia is
the most common hematological abnormality among the
patients undergoing major elective surgery [2]. The preva-
lence of preoperative anemia ranges from 5% to 75%,
depending on patient susceptibilities and the proposed
surgical procedure [3]. Preoperative anemia is more com-
mon among older patients and those with chronic disease
such as heart failure, diabetes mellitus, chronic kidney dis-
ease, primary hematologic diseases, other inflammatory
diseases [4], and coronary artery disease [5,6]. Although
diagnosis and treatment of anemia preoperatively is essen-
tial to optimize the patient’s condition [7], preoperative
anemia treatment is not a priority for most surgeons [8].
Epidemiology of blood transfusion and outcomes
Preoperative anemia has been associated with an increased
risk for 30-day mortality [9,10]. Preoperative anemia has
also been shown to be an independent risk factor for peri-
operative red blood cell (RBC) transfusion and for postop-
erative morbidity [11]. Major morbid outcomes include
transfusion-related acute lung injury (TRALI) [12], nosoco-
mial infections [13], increased graft occlusion after coron-
ary artery bypass grafting (CABG) [14], myocardial events,
neurological events, acute kidney injury [15], tumor re-
currence [16], and suppressed immune function [17]. In
a recent large study of 22,785 consecutive patients, in-
vestigators found that transfusing as little as 1 or 2 units
of RBCs was associated with increased morbidity and
mortality after cardiac surgery [18] supporting a previ-
ous systematic review of observational studies [19]. The
findings from these studies would imply that strategies
to reduce unnecessary RBC transfusions might be asso-
ciated with improved postoperative outcomes.
RBC transfusions are also associated with significant cost
related both to the product itself and the morbid events as-
sociated with unnecessary RBC transfusions which contrib-
ute to additional direct and indirect hospitalization costs
[20]. In a recent RBC transfusion cost analysis study, the
actual cost for each RBC unit was reported to range be-
tween US $522 and US $1,183 after calculating the direct
and indirect costs, which include consumables, laboratory
testing, nursing time, patient transport, treatment costs,
and staff fees resulting in increased cumulative total costs
[21]. This is substantially higher than previous estimates of
the cost of each RBC unit at US $250 to $550 [22].
National USA data [23] showed a decline in blood trans-
fusion usage estimate by 3% over each of the 2 years (2009
to 2010), and similar data [24] have been reported in the
UK as well. Although many therapeutic modalities have
been initiated to minimize the patients’ requirement forperioperative RBC transfusion, the rate of transfusion re-
mains unacceptably high and variable across both cardiac
(17 to 80%) [25,26] and non-cardiac major surgery [27].
These observations would imply that transfusion practices
are variable across patient, provider, and health system fac-
tors. This may stem from the absence of high-quality evi-
dence to guide the management of perioperative anemia
and blood conservation.
Strategies for perioperative blood conservation
A variety of contemporary perioperative pharmacologic and
non-pharmacologic blood conservation strategies (Table 1)
[28] have been proposed and variably adopted to minimize
RBC transfusion. In a recent study, the outcomes of 322
Jehovah’s Witness (JW) patients undergoing cardiac sur-
gery, who, for personal beliefs, refuse transfusion of all
blood products including RBCs, were evaluated. In this
study, JW patients had comparable long-term survival
to those willing to receive RBC transfusion in a propensity-
matched analysis; however, JW patients had fewer postop-
erative complications and shorter intensive care unit (ICU)
lengths of stay [29]. These provocative findings would
imply that many RBC transfusions might be unnecessary.
In fact, these data suggest that blood conservation strat-
egies, including preoperative treatment of anemia, may
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a trigger for RBC transfusion. In addition, a more recent
meta-analysis of randomized trials with 8,735 patients
showed lower risk of health care-associated infection for a
restrictive RBC transfusion strategy in comparison to a
liberal transfusion strategy in hospitalized patients [30].
Preoperative intervention: prophylactic iron therapy
Preoperative pharmacologic treatment of anemia has been
proposed to reduce perioperative RBC transfusion [31,32].
One potential strategy is the use of intravenous (IV) iron.
Iron is fundamental in RBC formation and is the most
common nutritional deficiency in both developed and de-
veloping countries [33]. A recent study [34] reported that
usage of oral iron to treat iron deficiency anemia is limited
by gastrointestinal absorption, particularly, in the patients
with associated acute or chronic diseases [35]. IV iron has
been reported to increase the hemoglobin (Hb) level and
to replenish iron stores more rapidly than oral iron formu-
lation in women with post-partum iron deficiency anemia
in a variety of RCT studies in other areas of medicine such
as post-partum hemorrhage [36], but in surgery, most
have been observational in nature. Consequently, pre-
operative IV iron has been proposed as an efficacious
strategy to increase serum hemoglobin and minimize ex-
posure to perioperative RBC transfusions [37,38].
To date, there is no broad consensus or established
clinical practice guideline to support the routine use of
prophylactic IV iron to treat anemia before major elect-
ive surgery. Moreover, additional questions about the
optimal timing of therapy, dose of iron, and whether
anemic patients need additional nutritional supplemen-
tation have yet to be answered. However, there are a few
guidelines recommending the use of IV for anemia in
surgical cases, but all are lacking class 1A evidence-
based medicine [39-41]. To date, there are relatively few
studies, the majority of which have been small and non-
definitive, that have evaluated the efficacy and safety of
IV iron preparations in patients undergoing major elect-
ive surgery. A recent meta-analysis [42] showed that
very low-quality evidence of IV iron results in modest
increases in hemoglobin levels compared with oral iron
or inactive control, but without clinical benefit. Unfor-
tunately, this meta-analysis was less homogeneous than
would be ideal, and they were not able to do subgroup
analyses for different types of participants (blood loss,
cancer, preoperative anemia, chronic heart failure, auto-
immune disorders, and infectious disease). In addition,
their literature search ended July 2013. Three other re-
cent studies have been published as well. The first is a
systematic review for RCTs with restricted language and
search time frame [43], the second is a systematic re-
view and meta-analysis for RCTs restricted to colorectal
surgery [44], and the third is a systematic literaturereview of RCTs and observational studies restricted to
cardiac surgery [45]. All three failed to find a sufficient
evidence to support the use of IV iron to decrease RBC
transfusion.
Accordingly, we propose to perform a systematic re-
view and evidence synthesis on the efficacy and safety of
IV iron therapy in the preoperative setting to treat anemia,
reduce transfusions, and improve outcome. This review
will capture recently published studies, will include a
broad range of elective surgery, and will not be limited to
English publications or RCTs.
Hypothesis
We hypothesize preoperative IV iron therapy will improve
preoperative hemoglobin concentrations in anemic pa-
tients undergoing major elective surgery, reduce the need
for RBC transfusion, and reduce complications compared
with placebo or standard of care. We will synthesize the
available data on the efficacy and safety of IV iron therapy
to increase hemoglobin levels, avoid transfusions, and im-
prove outcomes for anemic patients undergoing major
elective surgery.
Objectives
Perform a systematic review and evidence synthesis of
all randomized and quasi-randomized studies investigat-
ing (a) the efficacy of IV iron administration to improve
preoperative hemoglobin concentration and reduce RBC
transfusion rate, (b) the safety of IV iron formulations
with respect to adverse effects, and (c) the effectiveness
of IV iron administration to reduce perioperative major
morbidity and health resource use.
Methods/Design
Search strategy
In consultation with a health sciences librarian at the
John W. Scott Health Science Library at the University
of Alberta, we will search MEDLINE, EMBASE, EBM
Reviews, and the Cochrane-controlled trial registry in
the Cochrane library, Scopus, registries of health tech-
nology assessment and clinical trials, and Web of Sci-
ence. We will search the literature using the following
search terms: iron or dextran or Venofer or ferric or fer-
rous or ferrlecit AND anemi* or anaemi* AND preo-
perat* or postoperat* or perioperat* or operati* or surg*
or presurg* or postsurg* or perisurg* AND random* or
trial or placebo*. An example of the search conducted in
MEDLINE is in Additional file 1.
In addition, we will contact our study drug manufacturer
for unpublished trials, and we will search the ProQuest
Dissertations and Theses database. Selected conference
proceedings in transfusion, hematology, and surgery will
also be searched.
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database to February 2015, supplemented by a manual
search of reference lists of retrieved trials. In addition, refer-
ence lists of prior reviews of similar topics will be searched
for relevant studies. Language will be unrestricted.Inclusion criteria
All the included articles have to fulfill these criteria:
▪ Designs included are randomized and
quasi-randomized studies in all different phases.
▪ Study compares any type of intravenous iron
administered preoperatively to placebo or standard
care.
▪ Study reports findings specific to adult humans.
▪ Study of patients undergoing any elective major
surgery (Additional file 2) including, but not limited
to, cardiac, thoracic, orthopedic, gastrointestinal,
brain, urological, or obstetric operations.
▪ Study patients have pre-treatment hemoglobin level
less than 12 g/dL.
▪ Study reports at least one of the two following
outcomes: absolute or relative change in
preoperative hemoglobin level and/or the proportion
of patients receiving perioperative allogeneic RBC
transfusion.Exclusion criteria
Any one of these criteria will result in a study being
excluded:
▪ Observational (non-experimental) studies, reviews,
opinion papers, letters to the editor, and studies with
no reported methodology.
▪ Studies with no adult-specific findings.
▪ Studies involving patients with pre-treatment
hemoglobin level greater than 12 g/dL.
▪ Studies using oral iron only.
▪ Studies using IV iron plus EPO.
▪ Studies of minimally invasive robotic and
laparoscopic surgery.Primary outcomes
Co-primary outcomes:
▪ Absolute and relative change in preoperative
hemoglobin concentration.
▪ Proportion of anemic patients who receive allogeneic
RBC transfusion at any time perioperatively.Secondary outcomes
These will focus mainly on safety-related outcomes:▪ Total number of units of blood or blood products
transfused perioperatively.
▪ All-cause mortality.
▪ Postoperative nosocomial infection (Additional file 2).
▪ TRALI (Additional file 2).
▪ Neurologic complications (Additional file 2).
▪ Acute kidney injury (Additional file 2).
▪ Any reported adverse reaction (Additional file 2).
▪ Any reported reaction or side effect (Additional
file 2) from receiving a RBC transfusion. These
may include, but are not limited to, hemolysis
of transfused red cells, alloimmunization,
development of antibodies against platelets or
white blood cells, post-transfusion purpura, graft
vs. host disease, infection; immunomodulation, and
iron overload.
▪ Serious adverse events (SAEs), including suspected
and serious unexpected serious adverse reactions
(SUSARs) (Additional file 2).
▪ ICU admission and/or readmission and length of
hospital stay.
Study screening
Two authors (AE and SM) will initially review titles and
abstracts to retrieve potentially relevant studies. Retrieved
studies will then be subjected to a second phase of screen-
ing for eligibility, as determined by the eligibility criteria
listed above. Reason(s) for ineligibility will be documented
for all studies excluded in the second phase of screening,
using pre-piloted forms. Disagreements will be resolved
through discussion or by a third reviewer (SB) if necessary.
We will provide the PRISMA study flow chart (Additional
file 3).
Data abstraction
Data will be abstracted from the reports of all the in-
cluded studies in duplicate and independently by two re-
viewers (AE and SM) on standardized and pre-piloted
data extraction forms (Additional file 4). For the studies
evaluating multiple treatment arms, comparisons will be
made between IV iron arm and standard care or placebo
arm only. Discrepancies in extracted data will be resolved
by consensus, or involving a third author (SB) where con-
sensus cannot be reached.
Abstracted data from each study will include the de-
tails on the following:
 Study design, methodology, analysis, funding source,
trial registration, and publication details.
 Aggregate participant demographic characteristics
(for example, age, sex, and race).
 Aggregate participant characteristics including
comorbid diseases and risk factors for anemia
(for example, diet, any cause of blood loss, chronic
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anemia, reasons/indications for major surgery).
 Dosage of drug administered, frequency, and
duration of use.
 Hematocrit monitoring.
 Iron-related blood tests including serum iron,
ferritin, transferrin, total iron-binding capacity (TIBC),
transferrin saturation (iron saturation of transferrin),
and unsaturated iron-binding capacity (UIBC).
 All primary and secondary outcomes reported.
 Study quality features (see below).
Assessment of methodological quality
To evaluate the risk of bias in both RCTs and quasi-
randomized trials, two independent reviewers will use the
Cochrane Collaboration’s tool for assessing risk of bias.
This tool provides a model to assess the following domains
of bias: random sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding of
outcome assessment, incompleteness of outcome data (at-
trition bias), blinding of outcome assessment (performance
and detection bias), selective outcome reporting (reporting
bias), and a priori-derived sample size calculations. Each
domain for each trial will have a ranking of “low,”
“unclear,” or “high” risk of bias, in accordance with the
Cochrane Collaboration’s approach (Additional file 5) [46].
Study synthesis plan
Analysis plan
We will report the results of our search in a PRISMA flow
chart, including the number of randomized and quasi-
randomized studies (with their citations), the number of
phase I, II, and III trials, and the number addressing our
primary and secondary outcomes and language of studies.
We will present tables outlining a) each study’s character-
istics, b) risk of bias for each study, and c) study results.
Randomized studies and quasi-randomized studies will be
presented in separate tables, and within each set of tables,
there will be further stratification by a) outcome addressed
(primary versus secondary), b) study phase, and c) high,
medium, and low risk of bias. This information will also
be summarized in the text and the main biases identified
for each study design and outcome.
The tables describing study characteristics will include
information abstracted from the studies as per the data
abstraction section above. A separate table will report
each study’s effect measures (findings) corresponding to
our primary and secondary outcomes as follows: risk ra-
tios (and their 95% confidence intervals) reflecting the
association between preoperative IV iron administration
and need for RBC transfusion, differences in change in
hemoglobin concentration (and statistical significant of
this difference) between those who do and do not re-
ceive IV iron, proportion and relative risk of unplannedICU admissions and of ICU readmissions in each group,
differences in hospital length of stay, and 30-day mortal-
ity in each group.
Meta-analysis
We will examine clinical homogeneity of the studies
first, followed by assessment of statistical homogeneity
by using Cochrane’s Q test and I2 statistics, with I2 > 40%
considered significant heterogeneity [47]. We anticipate
that there will be sufficient homogeneity across studies
to justify a pooled statistical synthesis; however, we will
conduct a qualitative synthesis if there is statistical het-
erogeneity. We consider the factors listed below as po-
tential sources of heterogeneity in studies.
Data from all trials fulfilling the eligibility criteria will
be pooled for meta-analysis using a random effects model
to accommodate the anticipated heterogeneity among
study results and assuming that the individual specific ef-
fects are uncorrelated with the exposure variables [48].
Weights will be assigned to reflect sample size differences.
For continuous outcomes (change in Hb concentration,
the number of transfused RBC among those transfused,
ICU, and hospital lengths of stay), we will calculate the
standardized mean difference (SMD) and test for group
differences using unpaired t-tests of Mann-Whitney as ap-
propriate with P < 0.05 signifying statistical significance.
The SMD is used as a summary effect size, anticipating
the included trials all assessing the same outcome. For
categorical outcomes (nosocomial infection, TRALI,
neurological complications, acute kidney injury, adverse
reactions, ICU admission and readmission), we will cal-
culate pooled relative risks (RR) with 95% confidence in-
tervals. Where studies report length of stay and 30-day
mortality using time to event analyses, we will calculate
pooled hazard ratios with 95% confidence intervals. The
meta-analysis will be performed in RevMan Version 5.3
software [49] and Stata V.13 (STATA Corp, College Sta-
tion, TX, USA) [50].
Sensitivity analysis, subgroup analysis, and meta-
regression analysis
We will conduct sensitivity analyses to assess the impact
of each trial on the overall results and to examine whether
an individual study is over-influencing the meta-analysis
result. We will do an additional sensitivity analyses by ex-
cluding studies with unclear or inadequate randomization.
With availability of at least three trials, we will conduct
the following subgroup analyses to explore heterogeneity
and to assess robustness of our results:
1. Cardiac versus non-cardiac;
2. Different IV iron preparations;
3. Hb level; trials with a mean Hb equal to or greater
than 10 g/dL;
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5. Excluding studies considered at high risk of bias
according to the Cochrane risk of bias tool.
Our ability to conduct this subgroup analysis will depend
on the information provided in the relevant studies. We
will use univariable and bivariable meta-regression analyses
to explore the impact of the following variables in each
study on the pooled effect estimates for the primary out-
come: age, sex, baseline ferritin level, baseline hemoglobin
level, baseline hematocrit value, total IV iron dose adminis-
tered, and the rate of patients requiring allogeneic blood
transfusion during or after the surgery. The effect of each
variable on the pooled effect size will be considered signifi-
cant when the P value of the change in the estimate is less
than 0.05 or when the 95% confidence intervals of the two
analyses do not overlap.
Assessment of publication biases
To identify possible publication bias, we will construct a
funnel plot of effect size against the inverse of standard
error in the studies. Deviation from this funnel may sug-
gest publication bias [51].
Grading the strength of the evidence
We will assess the overall quality of the evidence for each
outcome in the included trials using the Grading of Rec-
ommendations Assessment, Development, and Evaluation
(GRADE) approach [52].
Ethical issues
For our meta-analysis, we will not require a health re-
search ethics board review as all data will be sourced
from existing literature.
Discussion
Anemia is common in patients undergoing major surgery
[2]. Over the past two decades, a variety of contemporary
pharmacologic blood conservation strategies have been
adopted to address preoperative anemia in attempts to
minimize unnecessary RBC transfusion. However, the opti-
mal treatment is not yet known due to paucity of the ran-
domized trials, most of which are small and have negative
results, which may be a result of being underpowered to
detect a treatment effect. Consequently, current knowledge
implementation has been suboptimal, and there are no
high-quality available clinical practice guidelines to inform
best practice. A meta-analysis conducted by pooling these
studies may provide new and clinically useful information.
In attempts to minimize the impact of blood loss at the
time of surgery, and consequently to avoid RBC transfu-
sion, many treatment modalities have been tried, from ad-
vanced techniques in operative procedure and anesthesia
alongside with newer drugs to stimulate hematopoiesis toreplacing blood by transfusion. Although a large system-
atic review has shown that antifibrinolytic drugs reduce
blood loss and consequently the rate of RBC transfusion
[53,54], it would appear that these drugs, while reducing
blood loss, are associated with a hypercoagulable state
[55]. Similarly, thrombotic events are reported with the
erythropoiesis-stimulating agents [56]. Iron plays an
essential role in erythropoiesis and is a fundamental
component in RBC formation [57]. Thus, use of iron is
a compelling potential intervention to treat preoperative
anemia. However, existing evidence is uncertain [58,59].
In non-surgical settings, it has been shown that supplemen-
tation with IV iron usually results in higher hemoglobin
values [60]. Previously used intravenous iron preparations
such as iron sucrose (saccharate) and iron dextran have
been associated with side effects [61] and anaphylactic reac-
tions [62]. However, newer intravenous preparations, such
as Venofer® (iron (III)-hydroxide sucrose), have shown bet-
ter tolerability [63].
We propose to perform a systematic literature review
and meta-analysis evaluating the efficacy and safety of
IV iron administration to anemic patients undergoing
major surgery for reduce transfusions and perioperative
morbidity and mortality.
We hypothesize that IV iron is a safe and effective way
to treat preoperative anemia. We further hypothesize
that preoperative administration of IV iron will increase
the hemoglobin in anemic patients at risk for periopera-
tive RBC transfusion and reduce perioperative allogeneic
RBC transfusion, reduce major morbidity, and utilize
fewer health resources.
Strengths of our meta-analysis
– It will be a comprehensive search without restriction
for language and time frame.
– It will include only experimental designs (RCTs and
quasi-randomized studies) to avoid selection bias.
– We will do critical appraisals of methodological
quality for the RCT enabling us to determine whether
the pooled findings are affected by study quality.
Limitations
Our meta-analysis might have the same unintentional
biases as any meta-analysis, and these potential biases
include
1. Study selection process may inadvertently exclude
relevant studies.
2. Standard methods used to conduct meta-analyses
may introduce bias if studies are not sufficiently
homogeneous.
3. Insufficient quantity or poor quality of the included
studies.
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meta-analysis
These will be guided by our final results. We expect that
this study will provide the impetus for future large-scale
RCTs in this field.
Additional files
Additional file 1: Search strategy. Sample search strategy for Medline
search.
Additional file 2: Definitions. Definitions of terms used in the report.
Additional file 3: PRISMA study flow chart. PRISMA flow chart
detailing included and excluded articles at each screening stage.
Additional file 4: Data extraction forms. Forms used to extract data
from studies.
Additional file 5: Risk of bias detection. Cochrane risk of bias tool.
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